The pharma company has completed the purchase of worldwide exclusive Intellectual Property Rights for Fondaparinux sodium, its generic anti-coagulant drug, from Australian partner Alchemia for $17.5 million.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
